Supernus Pharmaceuticals (SUPN) Cash from Investing Activities (2011 - 2026)

Supernus Pharmaceuticals has reported Cash from Investing Activities for 16 years, with the latest figure at $7.1 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at $7.1 million, up 123.18% year-over-year; the trailing twelve-month figure through Jun 2026 was -$14.7 million (up 82.24% YoY), and the FY2025 annual result was $4.1 million, up 102.16% from the prior year.
• Cash from Investing Activities grew to $7.1 million in Q2 2026, from -$19.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $239.8 million in Q1 2023 and troughed at -$82.2 million in Q3 2022.
• A 5-year average of -$8.1 million and a median of -$24.9 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2022, when Cash from Investing Activities tumbled 1341.65%; it then soared 484.57% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$48.8 million in 2022, then plunged by 35.3% to -$66.0 million in 2023, then jumped by 80.85% to -$12.6 million in 2024, then slumped by 306.0% to -$51.3 million in 2025, then jumped by 113.83% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $7.1 million in Q2 2026, -$19.2 million in Q1 2026, and -$51.3 million in Q4 2025.